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Peripherally derived angiotensin converting
enzyme-enhanced macrophages alleviate
Alzheimer-related disease
Maya Koronyo-Hamaoui,1,2 Julia Sheyn,1 Eric Y. Hayden,3 Songlin Li,1,4 Dieu-Trang Fuchs,1
Giovanna C. Regis,1 Dahabada H.J. Lopes,1 Keith L. Black,1 Kenneth E. Bernstein,2
David B. Teplow,3 Sebastien Fuchs,5 Yosef Koronyo1, and Altan Rentsendorj1,
These authors contributed equally to this work.
Targeted overexpression of angiotensin-converting enzyme (ACE), an amyloid-b protein degrading enzyme, to brain resident
microglia and peripheral myelomonocytes (ACE10 model) substantially diminished Alzheimer’s-like disease in double-transgenic
APPSWE/PS1E9 (AD
+) mice. In this study, we explored the impact of selective and transient angiotensin-converting enzyme
overexpression on macrophage behaviour and the relative contribution of bone marrow-derived ACE10 macrophages, but not
microglia, in attenuating disease progression. To this end, two in vivo approaches were applied in AD+ mice: (i) ACE10/GFP+ bone
marrow transplantation with head shielding; and (ii) adoptive transfer of CD115+ -ACE10/GFP+ monocytes to the peripheral blood.
Extensive in vitro studies were further undertaken to establish the unique ACE10-macrophage phenotype(s) in response to amyloid-
b1-42 fibrils and oligomers. The combined in vivo approaches showed that increased cerebral infiltration of ACE
10 as compared to
wild-type monocytes (3-fold increase; P 5 0.05) led to reductions in cerebral soluble amyloid-b1-42, vascular and parenchymal
amyloid-b deposits, and astrocytosis (31%, 47–80%, and 33%, respectively; P 5 0.05–0.0001). ACE10 macrophages surrounded
brain and retinal amyloid-b plaques and expressed 3.2-fold higher insulin-like growth factor-1 (P 5 0.01) and 60% lower
tumour necrosis factor-a (P 5 0.05). Importantly, blood enrichment with CD115+ -ACE10 monocytes in symptomatic AD+ mice
resulted in pronounced synaptic and cognitive preservation (P 5 0.05–0.001). In vitro analysis of macrophage response to well-
defined amyloid-b1-42 conformers (fibrils, prion rod-like structures, and stabilized soluble oligomers) revealed extensive resistance to
amyloid-b1-42 species by ACE
10 macrophages. They exhibited 2–5-fold increased surface binding to amyloid-b conformers as well
as substantially more effective amyloid-b1-42 uptake, at least 8-fold higher than those of wild-type macrophages (P 5 0.0001),
which were associated with enhanced expression of surface scavenger receptors (i.e. CD36, scavenger receptor class A member 1,
triggering receptor expressed on myeloid cells 2, CD163; P 5 0.05–0.0001), endosomal processing (P 5 0.05–0.0001), and 80%
increased extracellular degradation of amyloid-b1-42 (P 5 0.001). Beneficial ACE
10 phenotype was reversed by the angiotensin-
converting enzyme inhibitor (lisinopril) and thus was dependent on angiotensin-converting enzyme catalytic activity. Further,
ACE10 macrophages presented distinct anti-inflammatory (low inducible nitric oxide synthase and lower tumour necrosis factor-
a), pro-healing immune profiles (high insulin-like growth factor-1, elongated cell morphology), even following exposure to
Alzheimer’s-related amyloid-b1-42 oligomers. Overall, we provide the first evidence for therapeutic roles of angiotensin-converting
enzyme-overexpressing macrophages in preserving synapses and cognition, attenuating neuropathology and neuroinflammation,
and enhancing resistance to defined pathognomonic amyloid-b forms.
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Introduction
Neuroinflammation is a key feature of Alzheimer’s disease,
a relentless, progressive, and currently untreatable neurode-
generative disease and the leading cause of senile dementia
worldwide (Wyss-Coray, 2006; Gjoneska et al., 2015;
Heneka et al., 2015; Alzheimer’s Association, 2019). In
Alzheimer’s disease, the detrimental or therapeutic contri-
bution of peripherally derived monocytes, compared to that
of brain-resident microglia, is highly debated (Simard et al.,
2006; Ajami et al., 2007; Butovsky et al., 2007; El Khoury
et al., 2007; Mildner et al., 2007; Koronyo-Hamaoui et al.,
2009; Lebson et al., 2010; Bernstein et al., 2014b; Jay
et al., 2015a, b; Koronyo et al., 2015; Zuroff et al.,
2017; Cao and Zheng, 2018; Cronk et al., 2018; Da
Mesquita et al., 2018). Several studies have demonstrated
that monocytes can colonize diseased brain parenchyma in
murine models of Alzheimer’s disease (Simard et al., 2006;
Butovsky et al., 2007; Cronk et al., 2018) as well as under
irradiation-free physiological conditions (Koronyo-
Hamaoui et al., 2009; Lebson et al., 2010; Michaud et
al., 2013; Bernstein et al., 2014b; Koronyo et al., 2015;
Rentsendorj et al., 2018). In addition, heterogeneous sub-
populations of brain resident microglia have been identified
as having molecular signatures that are distinct from those
of peripheral monocytes, particularly disease-associated
microglia located proximal to the Alzheimer’s disease
pathological hallmark, amyloid-b plaques (Keren-Shaul et
al., 2017; Krasemann et al., 2017; Yin et al., 2017). These
microglial populations play a role in the pathogenesis of
chronic inflammation (Akiyama et al., 2000; Bales et al.,
2000; Colton et al., 2000; McGeer and McGeer, 2002;
Wyss-Coray, 2006; Prinz et al., 2011) and synaptic loss
by excessive pruning (Hong et al., 2016; Johnson and
Stevens, 2018), while insufficiently clearing misfolded amyl-
oid-b (Morgan et al., 2005; Simard et al., 2006; El Khoury
et al., 2007; Hickman et al., 2008; Koronyo-Hamaoui et
al., 2009; Yamanaka et al., 2012; Frenkel et al., 2013;
Roussos et al., 2015). In contrast, peripherally recruited
monocytes and macrophages in Alzheimer’s disease model
mice were shown to exhibit a neuroprotective phenotype,
regulating neuroinflammation and effectively eliminating
cerebral amyloid-b pathology (Butovsky et al., 2007;
Koronyo-Hamaoui et al., 2009; Bernstein et al., 2014b;
Koronyo et al., 2015; Rentsendorj et al., 2018). These
beneficial effects provide the rationale for a comprehensive
assessment of the therapeutic potential of peripheral mono-
cyte infusion in animal models and eventually in
Alzheimer’s disease patients.
The pathology of Alzheimer’s disease occurs as a com-
plex continuum, typically characterized by early accumula-
tion and aggregation of cerebral amyloid-b (Masters et al.,
2015; Jack et al., 2018) in the form of parenchymal pla-
ques and vascular deposits (e.g. cerebral amyloid angiopa-
thy, CAA) (Ellis et al., 1996), which extend to the
neurosensory retina in patients with Alzheimer’s disease
(Koronyo-Hamaoui et al., 2011; La Morgia et al., 2016;
Koronyo, 2017). The 42 amino acid-long form of amyloid-
b has been regarded as pathognomonic to Alzheimer’s dis-
ease, particularly its oligomeric forms, which display high
synaptotoxicity, disrupt long-term potentiation, and dir-
ectly induce cognitive impairments (Selkoe, 2008; Shankar
et al., 2008; Hayden and Teplow, 2012). At the same time,
the precise structural characterization and impact of vari-
ous amyloid-b42 species on cells have been challenging to
investigate because of their highly metastable nature and
their existence in dynamically changing mixtures (Walsh
and Selkoe, 2004; Glabe, 2005; Kirkitadze and Kowalska,
2005). To this end, methods have been developed to chem-
ically stabilize the different assembly types of amyloid-b42
such that a well-defined population of oligomers can be
studied (Bitan et al., 2003; Bitan and Teplow, 2004;
Hayden and Teplow, 2012; Lopes et al., 2012) in compari-
son with other naturally stable structures, including prion
rod-like enriched assemblies and fibrils (Walsh et al., 1997).
It is widely believed that approaches to target and remove
soluble amyloid-b42 oligomers from CNS tissues hold great
promise for curbing neuroinflammation and contributing to
Alzheimer’s disease prevention and therapy (Haass and
Selkoe, 2007; Viola and Klein, 2015).
In the past decade, strategies harnessing peripheral innate
immune cells such as monocytes and macrophages were
effective in clearing parenchymal and vascular amyloid-b
in the brain and attenuating progression in mouse models
of Alzheimer’s disease (Malm et al., 2005; Butovsky et al.,
2007; Town et al., 2008; Boissonneault et al., 2009;
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Koronyo-Hamaoui et al., 2009; Lebson et al., 2010;
Michaud et al., 2013; Bernstein et al., 2014b; Koronyo
et al., 2015; Ardura-Fabregat et al., 2017; Rentsendorj et
al., 2018). Importantly, even in the absence of whole-body
irradiation or microglial ablation via pharmacological inter-
vention, peripheral monocytes spontaneously engrafted into
the brain of transgenic APPswe/PS1E9 (AD
+) mice and
homed to amyloid-b plaque sites (Lebson et al., 2010;
Koronyo et al., 2015). In particular, enhanced recruitment
of cerebral amyloid-b-associated monocytes was achieved
through blood enrichment with bone marrow (BM)-derived
CD115+ monocyte subsets isolated from young donor
mice, leading to diminished neuropathology and preserved
cognitive function (Koronyo et al., 2015). To augment
these beneficial immune responses further, our group stu-
died a mouse model of Alzheimer’s disease in which the
animals were genetically modified to overexpress angioten-
sin-converting enzyme (ACE), an amyloid-b-degrading pep-
tidase, controlled by a c-fms promoter (Bernstein et al.,
2014b).
The role of ACE and ACE inhibitors in Alzheimer’s dis-
ease is complex (Kehoe et al., 2009). In humans, a recent
large genome-wide association meta-analysis (GWAS) of
94 437 individuals clinically diagnosed with late-onset
Alzheimer’s disease has corroborated previous studies and
identified ACE as a candidate gene (Kunkle et al., 2019). In
addition, GWAS-by-familial-proxy of Alzheimer’s or de-
mentia studies have further confirmed ACE relevance to
Alzheimer’s disease and identified the single nucleotide
polymorphism (SNP) combination of rs4343 and rs4351
in the ACE haplotype to possess a 45-fold increased risk
of developing Alzheimer’s disease (Meng et al., 2006;
Marioni et al., 2018). Importantly, individuals carrying
variants of the ACE gene (D/D alleles) resulting in
increased plasma expression of the enzyme were associated
with lower risk for Alzheimer’s disease (Kehoe et al., 1999;
Lehmann et al., 2005). Lower CSF levels of ACE and
higher brain ACE were also detected in Alzheimer’s disease
patients (Miners et al., 2008, 2009).
In our previous studies in mice, ACE was selectively ex-
pressed in myelomonocytic cells such as monocytes, macro-
phages, and microglia (Bernstein et al., 2014a, b). The
rationale for this experiment was 2-fold: myeloid cell
ACE overexpression markedly enhances innate immune re-
sponses (Shen et al., 2007; Koronyo-Hamaoui et al., 2014;
Bernstein et al., 2018), and surface expression of ACE
would promote amyloid-b42 cleavage and conversion into
shorter, more benign amyloid-b alloforms via ACE enzym-
atic activity (Hemming and Selkoe, 2005; Bernstein et al.,
2014b). In fact, AD+ mice overexpressing ACE in myelo-
monocytes displayed minimal to no Alzheimer’s disease-like
phenotype (Bernstein et al., 2014b). However, in those ex-
periments, ACE overexpression was present throughout the
life of the AD+ mice in both macrophages and microglia
due to an inserted genetic modification in the ACE gene.
Hence, the relative therapeutic contribution of a periodic
addition of peripherally derived ACE-overexpressing
monocytes and macrophages, as opposed to brain-resident
microglia, has yet to be investigated.
Here, we examine whether exogenous administration of
bone marrow-derived CD115+ myeloid cells overexpres-
sing ACE, either by bone marrow transplantation or by
peripheral blood enrichment, can also reduce the magni-
tude of disease. The use of bone marrow-derived myeloid
cells isolated from green fluorescent protein (GFP) mice
allowed unambiguous tracing of the grafted cells’ destiny
in the CNS of recipient animals; this was especially critical
to distinguish clearly between the contribution of microglia
and macrophages to the phenotype. Moreover, our experi-
ments showed that ACE10 monocytes and macrophages
were highly potent in clearing soluble and insoluble forms
of amyloid-b42, as well as in reducing neuropathology and
preserving synapses and cognitive function in murine
Alzheimer’s disease models.
Materials and methods
Mice used in the experiments
The mice selected to be recipients of bone marrow transplant-
ation or adoptive transfer of monocytes were from the
double-transgenic B6.Cg-Tg (APPSWE/PS1E9)85Dbo/Mmjax
hemizygous (AD+) mice strain (MMRRC stock #34832-
JAX|APP/PS1) and their non-transgenic littermates (as wild-
type control non-Alzheimer’s disease). These animals were pur-
chased from Jackson Laboratories and later bred and main-
tained at Cedars-Sinai Medical Center. For the bone marrow
transplantation experiment, we used 22 AD+ recipient mice
divided into three groups as follows: BMAD+ ::AD+ (n = 7,
four females and five males), BMWT::AD+ (n = 7, two females
and five males), and BMACE10::AD+ (n = 8, three females and
five males). For adoptive transfer experiments we used 30
mice, all males, divided into four groups as follows: AD+ re-
cipients of either wild-type monocytes (MoWT) (n = 8) or
MoACE10 (n = 8), PBS-injected AD+ controls (n = 7), and
non-transgenic naı¨ve wild-type mice (n = 7).
The ACE10/10 donor mice strain overexpresses ACE (two
alleles) in the myelomonocytic cell lineage (Supplementary
Fig. 1A and B) (Bernstein et al., 2014b). The Ace genotypes
used in this study were wild-type (ACEWT; n = 30) and homo-
zygous for the targeted allele (ACE10; n = 30). The GFP donor
mice were B6-TgN (b-act-EGFP) osbY01 (Okabe et al., 1997;
Okwan-Duodu et al., 2010), which had been backcrossed at
least 10 generations to a C57BL/6 background (Jackson
Laboratory; n = 15). This line has enhanced GFP (EGFP)
cDNA under the control of a chicken b-actin promoter and
a cytomegalovirus enhancer. These animals are also available
at Jackson Laboratory [C57BL/6-Tg(CAG-EGFP)10sb/J;
#003291].
The bone marrow donor mice strains (ACE10 and GFP) were
crossed to produce the genotypes GFP+AD–ACEWT (n = 76
mice), GFP+AD–ACE10 (n = 85), and GFP–AD+ACEWT (n =
4 mice) used for the in vivo experiments. Bone marrow trans-
plantation donor mice were 12–16 weeks old (n = 11, all
females). Adoptive transfer donor mice were used at the age
of 8–12 weeks old (n = 154, female and males at equal
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numbers). All mice used for these experiments were on the
genetic background of B6. All experiments were conducted
in accordance with Cedars-Sinai Medical Center Institutional
Animal Care and Use Committee (IACUC) guidelines under an
approved protocol.
Bone marrow transplantation
With their heads shielded, 2-month-old recipient AD+ mice
were subjected to 9.5 Gy (950 rad) irradiation for 11 min—
a dose lethal to proliferating cells. The cells were immediately
reconstituted by intravenous administration of 5  106 donor
marrow cells [isolated from 2-month-old GFP-expressing
donor mice (described above)]. As irradiation of the brain sig-
nificantly increases infiltration of immune cells, we protected
the mice brains from irradiation with an extensive lead-shield-
ing device that we had constructed (Supplementary Fig. 1C).
After 8 weeks of bone marrow repopulation, engraftment was
assessed by flow cytometry analysis of peripheral blood for
GFP expression. Non-invasive retinal imaging was carried
out when the mice reached 7 months of age. When they
were 8 months old, the recipient mice were anaesthetized
and perfused with 0.9% ice-cold saline containing 0.5 mM
EDTA. Brain, eyes, and blood were collected. Retinal flat-
mounts were immediately isolated and fixed in 2.5% parafor-
maldehyde (PFA) as previously described (Koronyo-Hamaoui
et al., 2011). One brain hemisphere was fixed for histology in
2.5% PFA containing 30% sucrose and the other hemisphere
was snap-frozen for further analysis.
Monocyte adoptive transfer
After the animals had been euthanized, bone marrow cells
were harvested and enriched for mononuclear cells on a
Ficoll density gradient as previously described (Koronyo
et al., 2015). Five to six million CD115+ -MoBM cells were
injected intravenously into each AD+ recipient mouse, begin-
ning when the animal was 8 months old and continuing once a
month for 3 months to ensure long-term elevated levels of
transfused monocytes. Animals in the control group received
intravenous injections of phosphate-buffered saline (PBS).
Characterization of isolated monocytes was performed by
flow cytometry. After completion of behavioural testing at
11 months old, the recipient mice were perfused, as described
above, to collect tissues for analysis.
Non-invasive retinal imaging
After deep anaesthesia had been induced in the animals, the
mouse pupils were dilated with 0.5% phenylephrine hydro-
chloride ophthalmic solution (Bausch and Lomb) combined
with 0.5% tropicamide ophthalmic solution (Mydral, Bausch
and Lomb). The retinas were imaged in vivo using the Micron
III microscope with predetermined light exposure time and in-
tensity, using identical gain and shutter modes for all animals
as previously described (Koronyo-Hamaoui et al., 2011;
Koronyo et al., 2012, 2017). Images and videos of the retina
were repeatedly captured at several angles to visualize a larger
retinal field and eliminate non-specific reflection signals.
Images were exported to ImageJ 1.46r for analysis.
Behavioural tests
To assess locomotor activity and cognitive functions of the
treated mice, we performed open field and Barnes maze tests,
as previously described (Koronyo et al., 2015). In the open
field test, each mouse was placed in an individual apparatus
for 60 min to record ambulatory and rearing activity. In the
Barnes maze test, the mice were first trained for 4 days (ac-
quisition-training phase), three times per day for 240 s for
each trial per mouse. Following a 2-day break, the mice
were retested for memory retention (retention phase, Day 7)
and then short-term memory (reversal phase on Days 8 and 9)
under the same conditions. Latency times and incorrect entries
(errors) were recorded manually and by using a video camera
(Koronyo et al., 2015).
Immunohistochemistry
Coronal brain sections (30 mm) and retinal flatmounts were
treated for 30 min in antigen-retrieval solution (Dako S1699)
prior to serum-free protein blocking (Dako X0909). Tissues
were then hybridized with various primary antibodies
(Table 1) overnight at 4C. Hybridization with primary anti-
bodies was followed by incubation with fluorophore-conju-
gated secondary antibodies (1 h at 37C) (Table 1). Stained
tissues were mounted using ProLong Gold with DAPI
(Molecular Probes, Life Technologies). Negative controls
were processed using the same protocol with the omission of
the primary antibody to assess non-specific labelling.
Thioflavin-S staining
For amyloid burden assessment in brain parenchyma and vas-
culature, sections were stained with Thioflavin S (Thio-S, 1%
w/v in 70% ethanol; Sigma-Aldrich) for 10 min at room tem-
perature, following the secondary antibody step, washed three
times in 70% ethanol for 1 min each, then rinsed in distilled
water before mounting.
Curcumin staining
Curcumin (diferuloylmethane; C21H20O6; Sigma-Aldrich) was
dissolved in 0.5 M NaOH followed by immediate dilution in
PBS to a final solution of 0.1 mg/ml curcumin (pH 7.9). Brain
sections were stained with curcumin solution for 10 min at
room temperature, and then rinsed three times with PBS for
5 min each, as previously reported (Koronyo-Hamaoui et al.,
2009).
Cerebral amyloid angiopathy scoring
Severity scores for the degree of CAA were defined by inspec-
tion of Thio-S-labelled brain sections using a scale of 0–4 (0 =
no CAA, 1 = low, 2 = medium, 3 = high and 4 = severe
CAA) (Wyss-Coray et al., 2001; Rentsendorj et al., 2018).
Eighteen images encompassing three to four brain sections
and covering both cortex (n = 9 images) and hippocampus
(n = 9) were analysed for each animal (total of n = 22
mice, n = 6–9 per experimental group).
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Primary culture of bone
marrow-derived macrophages
Bone marrow was harvested from the femora and tibiae of
wild-type or ACE10 mice donors after they had been eutha-
nized at the age of 8–12 weeks (3–5 mice/genotype), as previ-
ously described (Rentsendorj et al., 2018). Briefly, the cells
were cultured for 7 days in RPMI supplemented with 10%
foetal bovine serum (FBS), 100 U/ml antibiotic, 2 mM L-glu-
tamine, and 20 ng/ml MCSF. On the sixth day, macrophages
(M) were plated overnight in 24-well tissue culture plates
with or without glass coverslips (105 cells/well) depending on
which analysis was planned [immunocytochemistry (ICC) or
ELISA]. The following day, macrophages were either unstimu-
lated (not treated with amyloid-b) or stimulated by one of the
three amyloid-b42 alloforms (100 nM and 250 nM; fibril amyl-
oid-b42, prion rod-like amyloid-b42, oligomer amyloid-b42).
MACE10 were analysed as compared to MWT for cell-sur-
face amyloid-b42 binding; for this, the plates were chilled for
10 min on ice (0C) followed by addition of amyloid-b42 and
spun at 515 g for 1 min, followed by incubation for another
10 min at 0C (binding – 0’ time point). MACE10 were also
analysed for receptor expression as well as uptake of amyloid-
b42 forms at incremental time points from 5 min up to 60 min
(incubated at 37C; uptake –5, –15, –30 min). After each time
point, media were collected for biochemical analysis (ELISA).
The cells were rinsed with culture medium and then washed
with PBS before being fixed in cold methanol (–20C) for ICC.
In parallel, another subset of MACE10 were treated overnight
(in RPMI + 0.3% BSA) with lisinopril (1 mM) the day before
Table 1 List of antibodies used in the study
Antigen Source
species
Dilution Commercial source Catalogue #
IHC, ICC Primary antibodies
Arginase1 pAb Rabbit 1:100 Santa Cruz sc-20150
Beclin1 pAb Rabbit 1:100 Abcam ab16998
CD163 pAb Rabbit 1:100 Biorbyt Orb13303
CD204 mAb Scavenger R Type I/II (SCARA-1) Rat 1:100 AbD Serotec MCA1322
CD36 mAb clone MF3 Rat 1:200 Abcam ab80080
CD45 mAb clone 30-F11 Rat 1:25 BD Pharmingen #550539
EEA1 pAb Rabbit 1:100 Millipore 07-1820
GFAP mAb Rat 1:100 Invitrogen 13-0300
GFAP pAb Rabbit 1:100 Sigma-Aldrich G926
GFP pAb Rabbit 1:500 MBL #598
Human amyloid-b residues 17–24, mAb clone 4G8 Mouse 1:100 Covance/BioLegend 800711
Human amyloid-b residues 1–16, mAb clone 6E10 Mouse 1:100 Covance/BioLegend 803003
Iba1 pAb Rabbit 1:200 Wako Chemicals USA #019-19741
IGF1 pAb Goat 1:30 R&D systems AF791
iNOS mAb Rabbit 1:400 Cell Signaling 13120
Lamp1 mAb Rat 1:500 Abcam ab25245
Lamp2 mAb, clone M3/84 Rat 1:500 Millipore MABC24
MMP9 Goat 1:100 R&D systems AF909
PSD95 mAb Rabbit 1:600 Abcam ab76115
TREM2 pAb Goat 1:100 Abcam ab95470
VGluT1 pAb Guinea pig 1:6000 Millipore AB5905
Secondary antibodies
Cy2 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch
Laboratories
Cy3 (anti-mouse, rat, rabbit, goat, guinea pig IgG) Donkey 1:200 Jackson ImmunoResearch
Laboratories
Cy5 (anti-mouse, rat, rabbit, goat IgG) Donkey 1:200 Jackson ImmunoResearch
Laboratories
Flow cytometry CD11b mAb clone M1/70 (PE/Cy7) Rat 1 ml eBioscience/ThermoFisher 25-0112-81
CD45 mAb clone 30-F11 (PE) Rat 1 ml eBioscience/ThermoFisher 12-0451-81
F4/80 mAb clone BM8 (FITC) Rat 1 ml eBioscience/ThermoFisher 11-4801-81
Human amyloid-b residues 1–16, mAb clone 6E10 Mouse 1:500 Covance/BioLegend 803003
IL10 mAb clone JES5-16E3 (PerCP-Cy5.5) Rat 1 ml BioLegend 505028
Ly-6C mAb clone HK1.4 (eFluor450) Rat 1 ml eBioscience/ThermoFisher 48-5932-80
TGFb mAb clone TW7-16B4 (PerCP-Cy5.5) Mouse 1 ml BioLegend 141410
TNFa mAb clone MP6-XT22 (APC) Rat 1 ml BioLegend 506308
mAb = monoclonal antibody; pAb = polyclonal antibody.
1 ml = 1 ml per 100 000 – 1 000 000 cells.
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plating in 24-well plates and then exposed to 100 nM fibril
amyloid-b42 for 0, 5, or 30 min.
Primary culture of peritoneal-derived
macrophages
Peritoneal macrophages were collected from the peritoneum as
described previously (Okwan-Duodu et al., 2010). Briefly, the
macrophages were harvested from the peritoneal cavity 4 days
after a 2 ml intraperitoneal injection of 3% thioglycolate. The
cells were cultured at 37C, 5% CO2 in RPMI 1640 medium
enriched with 10% foetal calf serum, 50 mM 2-ME, 0.5 mM
sodium pyruvate, 10 mM HEPES buffer, 50 units/ml penicillin,
50 mg/ml streptomycin, and 2 mM L-glutamine. For purifica-
tion of the macrophages, peritoneal exudates were allowed to
adhere for 2 h, after which non-adherent cells were removed
with PBS to achieve 490% purity of macrophages.
Immunocytochemistry
Briefly, after serum-free protein blocking (Dako X0909), cells
were hybridized with various primary antibodies (Table 1) over-
night at 4C. The following day, these cells were incubated with
fluorophore-conjugated secondary antibodies (1 h at 37C).
Coverslips were mounted onto plates using ProLong Gold
with DAPI (Molecular Probes, Life Technologies).
Microscopy and quantification
A Karl Zeiss fluorescence microscope (Imager, Z1, ApoTome
and MBF equipped) was used for microscopic analysis. For
immunohistochemistry (IHC), three to six comparable coronal
brain sections, originally located 150 mm apart, were used for
quantitative analysis. For ICC, four to six samples were ana-
lysed. Numbers, area, and intensity of amyloid-b deposits,
GFAP+ and GFP+ cells, were determined automatically by
using NIH ImageJ software or an MBF stereological system.
The same approach was used to analyse cytokines and other
markers.
Image analysis
To cover the hippocampal area for synaptic analysis, 15 fields
per hippocampal area per brain were taken under 100 oil
objective lens and analysed (as previously described in
Koronyo et al., 2015). Single optical section images at 0.25
mm intervals and 3.75 mm Zeiss ApoTome high-resolution
scans were performed. Synaptic immunoreactive area and co-
localization of EEA1+ with 6E10+ immunoreactive area were
quantified using Puncta Analyzer as previously described
(Ippolito, 2010) and ImageJ (NIH) macro and batch process.
To quantify co-localized IGF1+ immunoreactive in mono-
cytes (Mo)/M (Iba1+CD45high cells), images were first com-
piled and analysed in Adobe Photoshop (Adobe Systems Inc.,
Mountain View, CA, USA). The per cent of IGF1+ foci were
obtained by tracing an outline around each plaque associated
with inflammation site. IGF1 (red) co-localizing with CD45
(green) was quantified by measuring the fluorescence of coin-
cident (yellow) particles. Frequency of coincidence of IGF1+
area co-localizing with Iba+CD45high cells in cortices was
plotted as percentage (%) in BMWT::AD+ versus
BMACE10::AD+ chimeric mice (n = 4–7 AD+ mice/group).
Elongation factor
The long and short axes of cells were manually measured in
micrometres from microscopic images using length tools in the
AxioVision Rel. 4.8 software package. At least 100 cells were
examined in each experiment in which individual cells were
assayed by microscopy.
Quantitative Meso Scale Discovery
protein assay
The Meso Scale Discovery (MSD) V-PLEX proinflammatory
Panel I (MSD K15048D-1) consists of highly sensitive multi-
plex ELISAs that quantitatively measure 10 cytokines (IFN-,
IL-10, IL-12p70, IL-1b, IL-2, IL-4, IL-5, IL-6, KC/GRO or
CXCL1, TNFa) using electrochemiluminescence detection
technology.
Preparation of standards/calibrators and samples
The highest calibrator (Calibrator 1) was prepared by adding
1 ml of Diluent 41 to the lyophilized calibrator vial according
to the manufacturer’s protocol. Seven calibrator solutions were
made by first transferring 100 ml of the highest calibrator into
300 ml of Diluent 41 and then making 4-fold serial dilutions
five additional times. Diluent 41 was used for the zero calibra-
tor. Sixty microlitres of each sample was mixed with 60 ml of
Diluent 41 to achieve a 2-fold dilution of each sample.
Plate preparation
A 1 wash buffer was made by a 20-fold dilution of the stock
(supplied in the kit) using deionized water. The plate was
washed with 150 ml of wash buffer three times and tapped
dry. Calibrators and samples (50 ml) were pipetted into the
assigned wells. The plate was incubated for 2 h at room tem-
perature on a shaker. To make 1 detection antibodies from
50 stock, 60 ml of each detection antibody for each analyte
was pipetted into 2.4 ml of Diluent 45. After the 2 h incuba-
tion, the plate was washed three times with wash buffer and
tapped dry. Each well received 25 ml of detection antibody
solution, after which the plate was incubated at room tempera-
ture with shaking for 2 h. To read the plate on the MSD
instrument (MESO Quicklex S 120), the plate was first
washed with 150 ml wash buffer three times and tapped dry,
then 150 ml of 2 Read Buffer (supplied in the kit) was
pipetted into each well. No incubation was needed after the
read buffer was added and before reading the plate.
Data analysis
The calculations used to establish calibration curves and de-
termine concentration and data analysis were carried out
using MSD Workbench 4.0 software. This software fits the
standard curves using a four parameter logistic fit with 1/y2
weighting.
Brain/plasma amyloid-b1-42 and
amyloid-b1-40 levels by ELISA
Fresh-frozen brain tissues were thoroughly homogenized in
PBS buffer with 0.5% TritonTM X-100 (Sigma) and 1% pro-
tease inhibitor cocktail set I (Calbiochem) and then processed
as previously described (Koronyo et al., 2015). Blood was
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immediately centrifuged after collection (730g for 10 min at
4C) for plasma isolation. After determination of protein con-
centration with the aid of the Pierce BCA Protein Assay Kit
(Thermo Scientific), concentrations of amyloid-b42 (Invitrogen
KHB441) in the soluble and insoluble brain protein fractions
and amyloid-b40 (Invitrogen KHB3481) in the plasma were
analysed using a sandwich ELISA kit (Invitrogen) as per the
manufacturer’s instructions.
Cell viability assay
Amyloid-b42 films were dissolved in 60 mM NaOH, soni-
cated for 1 min in an ultra-bath sonicator, and diluted into
cell culture media to the desired concentration. Aliquots of
10 ml were added to individual wells of 96-well microplates.
Each well contained 30 000 cells in a volume of 90 ml. After
an incubation lasting 15 h, 15 ml of MTT reagent was
added to each well and the cells were incubated for 3 h at
37C. SDS DMF HCl acetic acid stop solution (100 ml) was
added to each well, and the plates were incubated overnight
in the dark to ensure complete solubilization. The plates were
then read using a microplate reader, and the absorbance at
570 nm (formazan product) minus the absorbance at 630 nm
(background) was recorded. Controls included cells treated
with NaOH only and 1 mM staurosporine (to induce apop-
tosis and yield maximal cell death). A minimum of six repli-
cates were done for each treatment group, and the data from
three independent experiments were combined and reported
as mean  standard error of the mean (SEM). The biological
activity of amyloid-b was compared using the one-way ana-
lysis of variance Tukey test.
Preparation of low molecular weight
amyloid-b42
Low molecular weight (LMW) 99% HPLC purified amyloid-
b42 peptide was synthesized in the UCLA Biopolymer
Laboratory (Bitan and Teplow, 2005) or purchased from
AnaSpec. Aggregate-free amyloid-b42 (LMW amyloid-b) was
prepared as follows: Microcon YM-30 filters (EMD
Millipore) were washed with 200 ml distilled deionized
water. Amyloid-b was dissolved in 10% (v/v) 60 mM NaOH
and 90% (v/v) 10 mM phosphate buffer, pH 7.4, at a concen-
tration of 1 mg/ml. The solution was sonicated for 1 min and
then placed into the washed 30 kDa filter. Following centrifu-
gation at 14 000g for 20 min, the filtrate, LMW amyloid-b,
was collected, and its concentration determined by optical ab-
sorption spectroscopy using a molar extinction coefficient of
1280 M–1cm–1 at 276 nm. Purified peptides were stored as
lyophilizates at –20C.
Preparation of amyloid-b42 fibrils
For fibrillar amyloid-b42, LMW amyloid-b42 was prepared as
described above, and the peptide preparation was incubated at
100 mM with orbital shaking at 37C until fibril formation
occurred, 2 weeks (Koronyo et al., 2015). The presence of
fibrils was confirmed by electron microscopy.
Preparation of PICUP oligomeric
amyloid-b42
LMW amyloid-b was stabilized to ‘freeze’ oligomers using
photo-induced cross-linking of unmodified proteins (PICUP)
(Bitan et al., 2001, 2003; Bitan and Teplow, 2004; Bitan,
2006) to yield a distribution of ‘oligomeric amyloid-b’.
Briefly, 2 mM Tris(2,20-bipyridyl)dichlororuthenium(II) hexa-
hydrate [Ru(Bpy)3] (Aldrich) and 40 mM ammonium persul-
phate (APS) (Sigma) were prepared in distilled deionized water.
An 18-ml aliquot of 80 mM LMW amyloid-b was placed in a
PCR tube, followed by 1 ml Ru(Bpy)3 and 1 ml APS. The
sample was irradiated (150 W incandescent lamp) for 1 s,
and the reaction was quenched immediately with 1 M dithio-
threitol. Cross-linking reagents were removed by dialysis using
3.5 kDa MWCO Slide-A-Lyzer cassettes (Pierce) against 10
mM sodium phosphate, pH 7.4. More than five changes of
buffer were completed, and the protein purity and concentra-
tion were confirmed using optical absorption spectroscopy.
Preparation of prion rod-like
amyloid-b42
LMW amyloid-b42 was prepared as described above, and the
peptide preparation was diluted to 100 mM, incubated at room
temperature without agitation for 9 h, and flash frozen.
Transmission electron microscopy
Ten microlitres of sample were spotted onto 400-mesh carbon-
coated Formvar grids (Electron Microscopy Sciences) and incu-
bated for 2 min. Each grid was then negatively stained with a
1% (v/v) solution of uranyl acetate (Ted Pella), passed through
a 0.2-mm filter, which was immediately wicked off. TEM ana-
lysis was carried out using a JEOL 1200 EX at 80 kV
(Fradinger et al., 2005).
Flow cytometry
Brain tissues
After perfusion, the mouse brains were minced and digested
for 30 min with 1.5 mg/ml collagenase IV (Worthington
Biochemical Corp.) and DNase I (Stem Cell Technologies) at
37C. After centrifugation, homogenization and washing, the
pellet was suspended in 70% Percoll (GE Healthcare) and
then layered under a 30%/50% Percoll step gradient. After
30 min of centrifugation at 800g at 4C (without break),
mononuclear cells at the interface of the 70% and 50%
layers were collected and washed. For surface marker staining,
the cells were blocked and stained (Table 1). For intracellular
staining, the cells were fixed (eBioscience; #00-8222-49), per-
meabilized (eBioscience: #00-8333-56), and then stained
(Table 1). Cells were treated with brefeldin A to stain for se-
creted cytokines (eBioscience: #00-4506-51).
In vitro assessment of fibril amyloid-b42 phagocytosis
Primary bone marrow or peritoneal-derived CD115+ macro-
phages (wild-type and ACE10) were exposed to preformed 1
nM HiLyteTM Fluor 647 amyloid-b1-42 (Anaspec) fibrils. At
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specific time points (0, 15 and 60 min), the cells were stained
and analysed by flow cytometry.
Data and statistical analysis
Data were analysed using GraphPad Prism v. 7.01 (GraphPad)
software. Normally distributed data resulting from the IHC,
ELISA, and flow cytometry analyses are expressed as means
 SEMs. One-way or two-way ANOVA with Sidak’s and
Bonferroni’s post-tests was used for multiple comparisons
(three or more means). The threshold for statistical significance
was set at 0.05. For most behavioural testing, a power of 80%
was obtained with 8–10 animals per group. For stereology or
other semi- or fully quantitative analysis (i.e. q-IHC, ELISA), 6–
8 mice per group have sufficient power to detect significance.
Two-group comparisons were analysed using a paired or un-
paired Student t-test. The statistical association between two or
more variables was determined using Pearson’s correlation co-
efficient (r) test (GraphPad Prism) with corrections for multiple
analyses. Pearson’s r indicates direction and strength of the
linear relationship between two variables. Results are shown
as mean  SEM. Degrees of significance between groups are
represented as follows: \P 5 0.05, \\P 5 0.01, \\\P 50 .001,
and \\\\P 5 0.0001.
Data availability
The data that support the findings of this study are available
from the corresponding author, upon reasonable request.
Results
Reduced pathology in AD+ mice after
partial ACE10 bone marrow replace-
ment linked to brain and retinal
monocyte recruitment
In our initial experiment, we tested bone marrow transplant-
ation in APPSWE/PS1E9 double-transgenic mice (AD
+ mice).
Two-month-old mice (n = 22) received a high dose of radi-
ation while placed inside a head-shielding device.
Immediately afterward, the animals received an intravenous
injection of either AD+ bone marrow (GFP–AD+ACEWT;
n = 7, three females and four males), control bone
marrow (GFP+AD–ACEWT; n = 7, two females and five
males), or ACE10 bone marrow (GFP+AD–ACE10; n = 8,
three females and five males) (Fig. 1A and Supplementary
Fig. 1A–C). Blood analysis 8 weeks post-transplantation
showed that our protocol resulted in mice with chimeric
bone marrow consisting of 30–40% of cells from donor
origin. At 7 months, the two groups with GFP-labelled bone
marrow were examined using non-invasive retinal fluores-
cence imaging (Supplementary Fig. 1D) to track infiltration
of GFP monocytes to CNS tissue using a rodent retinal
Micron-III microscope (Koronyo et al., 2012, 2017). AD+
chimeric mice with BMWT had inflammatory cells surround-
ing amyloid-b plaques, including peripheral bone marrow-
derived GFP+CD45hi monocytes (Fig. 1B). Analyses demon-
strated reductions in amyloid-b plaque area (6E10+), soluble
brain amyloid-b1-42 levels (ELISA), GFAP
+ cells, and
GFAP+ area in mice that had received ACE10 bone
marrow compared to AD+ control mice (47%, 31%, 33%
and 33% decreases, respectively) (Fig. 1C–F). Figure 1G and
H demonstrate less cortical amyloid-b plaques stained with
curcumin, a method previously described (Koronyo-
Hamaoui et al., 2009, 2011; Koronyo et al., 2017), and
lower cortical GFAP+ astrocytosis. Interestingly, these effects
were localized in the brain as no significant differences in
plasma levels of amyloid-b1-40 and amyloid-b1-42 (ELISA) or
their ratios were observed between the experimental groups
(Supplementary Fig. 1E). Further, no significant differences
were noted between females and males.
To characterize the types of infiltrating inflammatory
cells within AD+ mouse brains, flow cytometry was used
to quantitate brain inflammatory populations as indicated
in Fig. 1I–L and Supplementary Fig. 1F–I. Side scatter and
forward scatter, along with biomarkers of haematopoietic
myelomonocytic cells such as CD11b, CD45, Ly6C, and
F4/80, were identified and quantified in the brain within
the GFP-negative (endogenous cells) versus GFP-positive
(bone marrow-derived donor cells) populations (Fig. 1I
and J). Furthermore, analyses of the expression of the
three cytokines TNFa, TGFb, and IL10 within these inflam-
matory cells in the brain were included. These analyses
showed the presence of both GFP+ donor monocytes in
the brains of AD+ animals, with a nearly 3-fold increase
in ACE10 compared to ACEWT monocytes
(CD11b+CD45hiLy6Cint/hi; Fig. 1K; P = 0.0101), while
the microglia populations (GFP–CD11b+CD45int/
lowLy6Clow) were unchanged (data not shown).
Given the importance of TNFa in the induction of pro-
inflammatory macrophage polarization and the pathogen-
esis of Alzheimer’s disease, we examined TNFa expression
by both GFP–CD11b+CD45low-int microglia and brain-infil-
trating GFP+CD11b+CD45hiLy6Cint-hiF4/80hi macro-
phages (Fig. 1L and Supplementary Fig. 1F and G). With
regards to microglia, there was no difference in TNFa in
any of the groups of mice (Supplementary Fig. 1F). In con-
trast, there was a significant and substantial 62% decrease
in TNFa expression in ACE10 macrophages in those AD+
animals that had received GFP+ACE10 bone marrow rather
than GFP+ACEWT bone marrow (P 5 0.05; Fig. 1L).
Further, our flow cytometry analysis into the chimeric
AD+ACE10 mouse brains allowed us to compare TNFa
in cerebral macrophages from endogenous, non-GFP
(wild-type for ACE expression) versus donor marrow,
GFP+ (with overexpression of ACE) sources in individual
mice (Supplementary Fig. 1G). We found that those macro-
phages overexpressing ACE produced 58% less cerebral
TNFa (P 5 0.05). No significant differences were detected
in TGFb and IL10 levels in cerebral macrophages of chi-
meric AD+ mice (Supplementary Fig. 1H and I).
To investigate cerebral ACE10 macrophage phenotype
further, we assessed insulin-like growth factor 1 (IGF1),
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Figure 1 Beneficial effects of partial ACE10 bone marrow transplantation in APPSWE/PS1E9 transgenic mice. (A) Schematic
illustration of experimental design and timeline. At 2 months of age, three groups of double-transgenic APPSWE/PS1E9 (AD
+ ) recipient mice (n =
22) underwent an irradiation procedure, with their heads shielded by a 3-inch-thick lead block. Mice then received a lethal dose of 950 rad
irradiation for 11 min (Supplementary Fig. 1A–C). Immediately after irradiation, AD + recipient mice received an intravenous (i.v.) injection of 5
million bone marrow cells from one of three types of donor mice: GFP–AD + ACEWT, GFP + AD–ACEWT, or GFP + AD–ACE10. The resulting
BMWT::AD + , BMACE10::AD + , and BMAD+ ::AD + chimeric mice (n = 7–8 per group) had a partial (30–40%) bone marrow transplantation. The
two groups of GFP-labelled bone marrow chimeric AD + mice underwent retinal imaging at 7 months of age. Tissues were harvested for analysis
from all three experimental groups when the animals were 8 months of age; the left hemisphere was used for flow cytometry, the right hindbrain
for histology, and the right forebrain for protein analysis. (B) Representative fluorescence micrograph of the BMWT::AD + chimeric mouse brain
showing infiltrating monocytes (GFP + /CD45hi; arrows) near a 6E10+ amyloid-b plaque site. Scale bar = 20 mm. (C) Quantitative IHC analysis of
6E10 + amyloid-b plaque areas in brain cortices (Ctx) of BMWT::AD + , BMACE10::AD + , and BMAD + ::AD + chimeric mice (n = 5–7 mice/group).
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associated with anti-inflammatory and neuro-regenerative
functions (Gasparini and Xu, 2003; Butovsky et al., 2006;
Koronyo-Hamaoui et al., 2009; Han et al., 2016; Bianchi
et al., 2017; Spadaro et al., 2017; Vannella and Wynn,
2017) in the brains of chimeric AD+ACE10 mice com-
pared to control mice (Fig. 1M and N and
Supplementary Fig. 1J–O). Our immunohistochemistry
data demonstrate a consistent 2.3-fold increase in cerebral
IGF1 expression, and further, a substantial 2.5-fold in-
crease surrounding Thio-S + amyloid-b plaques in chimeric
AD+ACE10 mice (Supplementary Fig. 1K and L; P 5 0.05
and 0.0001). Moreover, cerebral IGF1 was predominantly
expressed by Iba1+CD45high brain-infiltrating monocytes
and macrophages, with a significant 3.2-fold elevation of
IGF1 expression in brain macrophages in chimeric
AD+ACE10 mice (Fig. 1M and N and Supplementary
Fig. 1M and N; P 5 0.01). A tight correlation was
observed between cerebral IGF1 immunoreactive area
and co-localized IGF1 within macrophages
(Supplementary Fig. 1O; Pearson’s r = 0.92, P 5
0.0001), suggesting that infiltrating monocyte/macro-
phages are the main source of IGF1 in these chimeric
AD+ mice. Thus, there appears to be a fundamental dif-
ference between wild-type and ACE10 macrophages in
their responses to an identical inflammatory environment
induced by Alzheimer’s disease in the brain.
Figure 1O–Q shows non-invasive retinal images from
live AD+ mice that had received bone marrow transplant-
ation with either non-GFP AD+ACEWT (Fig. 1O), GFP+ -
AD–ACEWT (Fig. 1P and P’), or GFP+ -AD–ACE10
(Fig. 1Q). Numerous macrophages within the retina were
observed (Fig. 1P and Q). Supplementary Videos 1 and 2
demonstrate the ability to track individual GFP+ immune
cells derived from wild-type and ACE10 bone marrow, re-
spectively, in the live retina of an Alzheimer’s disease model
mouse. Further, detailed histological examination of ex
vivo retinal immunohistochemistry imaging documents
homing of ACE10 macrophages to amyloid-b plaque
(Fig. 1R). This was seen far more consistently in those ani-
mals that had received bone marrow from ACE10 donors
than in animals that had received bone marrow from an
ACEWT origin (Fig. 1P and Q).
Synaptic and cognitive preservation
following peripheral blood
enrichment of CD115+ ACE10
monocytes
Another more translational strategy that we used to assess
the relative contribution and potential therapeutic effect of
ACE10 monocytes involved peripheral blood enrichment
with CD115+ monocytes. CD115 is the product of the
Csf1r gene; monocytes that express this marker are often
termed inflammatory monocytes and are recruited to
inflamed sites to mediate tissue repair (Valero et al.,
2017). Previous work from our laboratory has established
that adoptively transferred CD115+ wild-type monocytes
in AD+ mice directly ameliorate amyloid-b neuropathol-
ogy and lead to reduced neuroinflammation and preserva-
tion of cognitive function (Koronyo et al., 2015). Our
current findings demonstrate that ACE10 bone marrow
can further reduce the neuropathology in AD+ mice
more than ACEWT bone marrow; hence, the next step
Figure 1 Continued
(D) Sandwich ELISA analysis of cerebral soluble amyloid-b42 levels in AD
+ chimeric mice (n = 6–8 mice/group). (E) Quantitative IHC analysis of
the cortical GFAP + reactive astrocyte cell count in AD + chimeric mice (n = 6–8 mice/group). (F) Quantitative IHC analysis of the cortical
GFAP+ reactive astrocyte area in AD + chimeric mice (n = 7 mice/group). (G) Representative micrographs of cortical amyloid-b plaques stained
with curcumin in BMWT::AD + versus BMACE10::AD + chimeric mice. (H) Representative micrographs of cortical GFAP + astrocytes in the same
experimental groups. Scale bar = 50 mm (for G and H). (I) Flow cytometry analysis for cerebral infiltrating GFP + monocytes in AD + chimeric
mice. Combinations of markers were used to identify microglia (CD11b + CD45int.-lowGFP) versus infiltrating monocyte subsets
(CD11b + CD45hiLy6ChiGFP + ). (J) Representative flow cytometry map analysis showing increased infiltration of CD11bhiCD45hiLy6ChiGFP +
ACE10 versus wild-type monocytes in AD + chimeric mice. (K and L) Quantitative flow cytometry analyses of cerebral inflammatory biomarkers
in chimeric AD + mice following partial bone marrow transplantation. (K) Percentage of GFP + CD11bhiCD45hiLy6ChiF4/80low monocytes (n = 5–
6 mice/group), (L) TNFa expression in infiltrating GFP + CD11b + CD45hiLy6Cint-hiF4/80hi Mf (n = 4–5 mice/group). (M) Fluorescent micrographs
of cortical brain regions stained against IGF1 (red) combined with Iba1 (white) CD45 (green) and nuclei (blue) in BMWT::AD + versus
BMACE10::AD + chimeric mice. Scale bars = 10 mm. Brain-infiltrating Iba1 + CD45hi Mo/Mf abundantly expressed IGF1 in BMACE10::AD + chimeric
mice (bottom). (N) Quantitative IHC of % IGF1 + area co-localized with Mo/Mf in BMWT::AD + versus BMACE10::AD + chimeric mice (n = 7 mice/
group). (O–Q) Representative non-invasive retinal fluorescence imaging of infiltrating GFP + bone marrow cells in living AD + chimeric mice. (O)
A control AD + mouse that underwent bone marrow transplantation of GFP–BMAD + (GFP–BMAD + ::AD + ). (P) Retinal fluorescent images from a
GFP + BMWT::AD + mouse (P’, enlarged image). (Q) Retinal fluorescent images from a GFP + BMACE10::AD + mouse (arrows indicate GFP + bone
marrow cells). (R) Representative microscopic image obtained during the histological examination of a retina extracted from a BMACE10::AD +
mouse whose retina had been previously imaged in vivo; ex vivo staining with GFP (green), CD45 (red), 4G8 (cyan), and DAPI (blue), validating the
homing of GFP + ACE10 monocytes to retinal amyloid-b plaques. Scale bar = 5 mm. Data from an individual mouse (filled circles for males and clear
circles for females) as well as group mean  SEM are shown. Fold increase and percentage decreases compared to control groups are shown in
green. P 5 0.05, P 5 0.01. ns = non-significant, using one-way ANOVA and Bonferroni’s post-test for three group comparisons. For two-
group comparisons, paired or unpaired two-tailed Student t-tests were used. Ab = amyloid-b; FS = forward scatter; SS = side scatter.
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was to test the effects of blood enrichment with CD115+
ACE10 monocytes (Fig. 2). The experimental procedure
and timeline for adoptive transfer studies can be found
in Fig. 2A–D (n = 23 AD+ experimental mice and n =
7 non-transgenic naı¨ve wild-type littermates; all males).
Controls for this experiment were recipient AD+ mice
that had received monthly intravenous injections of PBS
(vehicle). At 11 months, open field and Barnes maze be-
havioural tests were performed (Fig. 2E–K and
Supplementary Fig. 2A) as previously described
(Bernstein et al., 2014b; Koronyo et al., 2015). There
were no differences in locomotor activity, neither rearing
nor ambulatory movements, between any of the groups
(Fig. 2E and F). Substantial differences in performance
in the Barnes cognitive test, both in incorrect entries and
latency times, were recorded during the training phase of
the study and during the long-term memory retention and
reversal phases (Fig. 2G–K and Supplementary Fig.
2A–C). Adoptive transfer of CD115+ cells enhanced over-
all cognitive functions, with ACE10 monocytes consistently
showing a trend of extended improvement.
In the training phase, AD+ mice that had received
CD115+ monocytes with either ACEWT or ACE10
showed a pattern of maze learning that was essentially
identical to that of wild-type mice (Fig. 2G and
Supplementary Fig. 2A). In contrast, AD+ mice that had
received PBS displayed impaired training compared to wild-
type mice. In the long-term memory retention test (Day 7),
during the reversal phase (Day 8), and in the spatial
memory analysis at Day 9, we observed significant differ-
ences between mice receiving CD115+ ACE10 cells and
those receiving PBS controls. MoACE10-treated mice dis-
played a pattern of learning equivalent to that of wild-
type mice, which was also superior to recipients of the
MoWT cells (Fig. 2H–K and Supplementary Fig. 2B and C).
Immunohistochemical analysis of 6E10+ plaque area in
the hippocampus, cingulate cortex, and total brain shows
that AD+ mice that had received an infusion of CD115+
(predominantly ACE10) monocytes had fewer hippocam-
pal and total brain plaques than AD+ mice that had
received only PBS vehicle (P 5 0.05, Fig. 2L and
Supplementary Fig. 2D–F). Analysis of vascular Thio-S +
amyloid-b burden calculated as CAA score (Rentsendorj et
al., 2018) revealed significant 56% and 82% reductions in
CAA scores in AD+ mice recipients of both BMWT and
BMACE10, respectively, compared to the control group
(Fig. 2M and Supplementary Fig. 2I–M; P 5 0.0001). A
significant reduction in CAA scores was further noted in
recipients of BMACE10 versus BMWT in hippocampal and
cortical regions (Fig. 2M and Supplementary Fig. 2L and
M; P 5 0.05). Analysis of synaptic biomarkers indicated a
significant preservation of both pre- (VGluT1) and post-
(PSD-95) synapses by blood enrichment with CD115+
ACE10 monocytes, promoting synaptic protection
(Fig. 2N and Supplementary Fig. 2G and H; P 5 0.05–
P 5 0.001).
Enhanced binding and uptake of
pathological amyloid-b42 conformers
and surface expression of scavenger
receptors in ACE10 macrophages
Next, we characterized ACE-overexpressing macrophages
for their ability to recognize, bind, internalize, and process
defined structures of amyloid-b associated with Alzheimer’s
disease neuropathology. To this end, we performed an ex-
periment in which bone marrow cells were harvested from
wild-type and ACE10 mice and then cultured for 6 days
with MCSF to generate mature macrophages (Fig. 3A).
On Day 7, these cells were mixed with well-defined and
characterized populations of amyloid-b1-42 fibrils, amyl-
oid-b1-42 prion rod-like structures, or cross-linked-stabilized
soluble amyloid-b1-42 oligomers (Fig. 3A and B). The iden-
tity of amyloid-b products was confirmed by SDS-PAGE
and TEM (Fig. 3B and C). Another control group for
this experiment included untreated cells, which were not
exposed to amyloid-b. Figure 3D shows surface binding
of fibril amyloid-b42 to a class A type 1 scavenger receptor,
Scara1, on the cell membrane of ACE10 macrophages (0
min time point); macrophages were immunostained for
anti-amyloid-b (6E10), Scara1 (CD204), and nuclei
(DAPI; Fig. 3D).
Quantitative ICC analysis indicates substantial 4.9-fold
and 2-fold increases of surface fibril amyloid-b42 and oligo-
mer amyloid-b42 binding, respectively, in ACE
10 macro-
phages as compared with wild-type macrophages (Fig. 3E;
P = 0.001 and P = 0.02, respectively). Membrane scaven-
ger receptors such as Scara1, class B scavenger receptor
CD36, triggering receptor expressed on myeloid cells 2
(TREM2), and CD163 have been implicated in macrophage
activation and increased phagocytosis of amyloid-b in
Alzheimer’s disease (Hickman et al., 2008; Yamanaka
et al., 2012; Frenkel et al., 2013; Pey et al., 2014; Kim et
al., 2017). We observed significant increases in baseline
Scara1, TREM2, CD163, and CD36 surface expression in
untreated ACE10 versus wild-type macrophages (Fig. 3F,
Supplementary Fig. 3A and B and Supplementary Table
1; P 5 0.01–0.0001). These receptors have been associated
with Alzheimer’s disease and specifically facilitate amyloid-
b uptake by microglia and/or macrophages but have never
been studied in ACE10 macrophages or in response to
defined and stabilized populations of amyloid-b42 oligo-
mers. We also found that surface expression of TREM2
and Scara1 was increased in ACE10 macrophages at the
0-min time point and 5 min after exposure to fibril amyl-
oid-b42 (Fig. 3F–H and Supplementary Fig. 3C; P 5 0.05–
0.0001) but not in response to amyloid-b42 prion rod-like
structures or soluble oligomers (Fig. 3F and G). As early as
5 min after contact and phagocytosis of fibril amyloid-b42,
intracellular amyloid-b42 staining was visible in the cell
processes and soma of wild-type macrophages, and more
prominently in ACE10 macrophages (Fig. 3H). Interestingly,
baseline MHC-II expression was lower by 49% in the
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Figure 2 Cognitive preservation and restricted pathology following adoptive transfer of a CD115+ ACE10 monocyte subset in
AD+ mice transgenic mice. (A–C) Schematic representation of experimental procedure and treatment groups. (A) CD115 + monocytes
(MoBM) were isolated from the bone marrow of GFP + donor mice and enriched by MACS microbeads and an anti-CD115 antibody column
sorting procedure. (B) MoBM were then intravenously (i.v.) injected into the tail vein of AD + recipient mice (n = 8 mice/group, all males). (C)
Additional control groups included naı¨ve wild-type (WT) mice and AD + mice injected with PBS (n = 7 mice/group, all males). (D) Schematic
timeline of the in vivo preclinical experiment. Pre-symptomatic AD + mice exhibiting neuropathology at 8 months of age received monthly
injections of 5–6 million GFP + MoWT or GFP + MoACE10 or PBS for 3 months (immunization regimen indicated by green arrows). At 11 months,
mice underwent behavioural tests followed by tissue collection and analysis when 12 months of age. (E and F) Open field test in all AD +
treatment and naı¨ve wild-type groups measuring: (E) ambulatory and (F) rearing activity. (G–K) Cognitive functions assessed by the Barnes maze
test in both monocyte-treated groups as compared to the control PBS-injected group and naı¨ve cognitively normal wild-type group (n = 6–8 mice/
group). Incorrect entries (errors) for the following: (G) acquisition-training phase (Days 1–4), (H) memory retention (Day 7), (I) reversal phase
(Days 8 or 9), and (J and K) memory test at Day 9. (J) Errors and (K) escape latency (s). (L) Quantitative IHC analysis of 6E10 + amyloid-b plaque
areas in the hippocampus (HC), cingulate cortex (CC), and total brain in MoWT- and MoACE10-treated versus PBS-injected AD + mice (n = 7–8
mice/group). (M) CAA score assessed as vascular Thio-S + in AD + mice (n = 6–8 mice/group). Data from an individual mouse as well as group
mean  SEM are shown. (N) Quantitative IHC analysis of hippocampal pre-(VGluT1 + ) and postsynaptic (PSD95 + ) areas in MoACE10-treated mice
compared to PBS-injected control AD + and naı¨ve wild-type mice (n = 6–8 mice/group). Data from individual mice, lower and upper quartiles (as
lower and upper horizontal lines in box), median (midline within box), and minimum/maximum values (whiskers), are shown. Percentage increase
and decrease compared to control groups are shown in green. P5 0.05, P5 0.01, P5 0.001, P5 0.0001. ns = non-significant, by two-
way or one-way ANOVA and Bonferroni’s post-test. Significance between two-groups by unpaired two-tailed Student t-test. IR =
immunoreactive.
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Figure 3 Enhanced surface recognition and uptake of diverse amyloid-b42 conformers by ACE
10 macrophages. (A) Design and
timeline of in vitro. Bone marrow was isolated from young wild-type (WT) and ACE10 mice (8–12 weeks old) and cultured for 6 days in MCSF-
enriched media, generating primary macrophage cultures (MfWT and MfACE10, respectively). On Day 7, Mf were either unstimulated (Un) or
stimulated by one of the three amyloid-b forms: fibrils (fAb42), prion rod-like structures (pAb42), or cross-linked oligomers (oAb42). Mf
ACE10
were analysed and compared to control MfWT for cell surface amyloid-b42 binding (pre-chilled on ice; binding – 0 min) and receptor expression as
well as uptake of amyloid-b42 species at incremental time points from 5 min up to 60 min (incubated at 37C; uptake: 5, 15, 30 min). Cells and
media were isolated and further analysed using various methods including ICC, flow cytometry (FC), and quantitative protein analysis. (B) Forms
of non-cross-linked (non-XL) and cross-linked (oAb) amyloid-b42. Oligomers as large as an octamer are observed. (C) Negative stain TEM
micrographs of amyloid-b42 assemblies. Left: Fibrillar amyloid-b (fAb42) displayed long fibrils of 10 nm diameter with a twisted morphology
typically comprising two smaller filaments. Middle: Prion rod-like amyloid-b42 (pAb42) displayed short (5300 nm) straight rods comprising
multiple filaments (blue arrows). Narrower (5 nm) rod-like structures appeared to comprise twisted double filaments (black arrows). The
assembly indicated by the red arrow is shown in the inset at higher magnification. Right: Cross-linked oligomers (oAb42) displayed mainly quasi-
spherical assemblies (white arrows) with diameters of 5–8 nm. The assembly indicated by the red arrow is shown in the inset at higher
magnification. A rare rod-like structure (yellow asterisk) was also observed. Scale bars = 100 nm or 50 nm (insets). (D) Representative
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ACE10 macrophages (Supplementary Table 1; P 5 0.01). A
summary of key in vitro findings comparing ACE10 and
wild-type macrophages can be found in Supplementary
Table 1.
To assess the macrophages’ ability to uptake amyloid-b42
species at later time points (15, 30, and 60 min), we con-
ducted a series of experiments presented in Fig. 3I–U,
Supplementary Table 1, and Supplementary Fig. 3.
Figure 3I displays the major differences detected in macro-
phage uptake of different amyloid-b42 conformers after 15
min of exposure, with fibrils being the most efficiently pha-
gocytosed and soluble oligomers the least engulfed by these
cells (Supplementary Fig. 3D–F). Quantitative ICC analysis
shows that surface CD36 expression by ACE10 macro-
phages was substantially and consistently increased as com-
pared to wild-type macrophages (Fig. 3J; P 5 0.0001),
along with increased intracellular amyloid-b42 uptake 15
min after exposure to all three forms of amyloid-b
(Fig. 3K; P 5 0.05–0.0001). Moreover, the expression of
CD36 as well as the uptake of fibril amyloid-b42 at 5 and
30 min were found to be dependent on ACE catalytic ac-
tivity, since overnight treatment with the ACE inhibitor
lisinopril significantly decreased both (Fig. 3L and M).
Interestingly, in ACE10 macrophages treated with lisinopril,
CD36 expression was decreased and fibril amyloid-b42
uptake increased over time during a 30-min culture
period, while remaining substantially lower compared to
their values in the enzymatically uninhibited ACE10 macro-
phages (Fig. 3L and M). Supplementary Table 1 summar-
izes the main findings on amyloid-b surface binding and
uptake as well as the expression of scavenger receptors,
the immune profile, and the morphology of wild-type
versus ACE10 macrophages.
Analysis of discrete wild-type and ACE10 macrophage
populations to determine potential associations between
amyloid-b42 binding/uptake and surface expression of the
scavenger receptors Scara1 and CD36, using Pearson’s r
correlations, revealed strong and direct relationships in
both cell genotypes (Fig. 3N and O; r = 0.73, P =
0.0022 for wild-type; r = 0.71, P = 0.003 for ACE10, for
Scara1). Further, there were direct correlations between
amyloid-b42 fibril and amyloid-b42 oligomer uptake after
a 15-min incubation and the expression level of CD36 in
ACE10 macrophages (Fig. 3P and Q; r = 0.83 and P =
0.001 for fibril amyloid-b42; r = 0.42, P = 0.038 for oligo-
mer amyloid-b42). The strong correlation between CD36
expression and amyloid-b uptake was also true for prion
rod-like amyloid-b42 uptake after 15 min in both wild-type
and ACE10 macrophages (Supplementary Fig. 3K and L; r
= 0.83 and 0.76, respectively, and P 5 0.0001). Extended
correlations are shown in Supplementary Fig. 3G–L.
Using quantitative flow cytometry analysis, we validated
increased binding and uptake of fluorescently labelled
HiLyte 647-fibril amyloid-b42 in ACE
10 versus wild-type
macrophages, from both bone marrow and peritoneal
sources, as well as reversal effects following inhibition
of ACE catalytic domains (Fig. 3R–U and Supplementary
Fig. 3M–P). Flow cytometry-based quantitative analyses
confirmed the aforementioned ICC analysis and demon-
strated that the rate of amyloid-b42 fibril phagocytosis by
Figure 3 Continued
fluorescence micrograph of MfACE10 prestimulated with fibril amyloid-b42 on ice (at the 0-min time point) and immunolabelled for Scara1 (red),
human amyloid-b (6E10; green), and nuclei (blue). Abundance of co-surface labelling of Scara1 + and fibril amyloid-b42 (yellow spots) on the
MfACE10 cell body and processes was detected, indicating large amounts of fibril amyloid-b42 bound to surface Scara1. (E) Quantitative ICC
analysis of a 6E10 + immunoreactive (IR) area for cell surface binding of the three amyloid-b42 species (250 nM each) at the 0-min time point in
MfACE10 versus MfWT. (F) Quantitative ICC analysis of surface Scara1 expression in ACE10 versus wild-type Mf that were either untreated or in
the presence of different amyloid-b42 forms at the 0-min time point. (G) Quantitative ICC analysis of TREM2 expression in ACE
10 versus wild-
type Mf following prestimulation by the different forms of amyloid-b42 (250 nM each). (H) Representative fluorescence micrograph of Mf
WT and
MfACE10 cells that were incubated for 5 min with 250 nM fibril amyloid-b42 and later immunolabelled for Scara1 (red), human amyloid-b (6E10;
green), and nuclei (blue). Amyloid-b42 fibrils are seen in intracellular vesicles within these phagocytic cells (white arrow). (I) Panel of repre-
sentative fluorescence micrographs of MfWT and MfACE10 cells following a 15-min incubation with three different amyloid-b42 forms immu-
nolabelled for scavenger receptor type B CD36 (purple), human amyloid-b (6E10; green), and nuclei (blue). (I’) Separated single channel (cy2) for
intracellular amyloid-b42 uptake. (J) Quantitative ICC analysis of CD36 expression (mm
2/cell number) in ACE10 versus wild-type Mf that were
either untreated or exposed to different amyloid-b42 forms (250 nM) for 15 min. (K) Quantitative ICC analysis of 6E10
+ immune-reactive area
(mm2/cell number) for intracellular uptake of the three amyloid-b42 species (250 nM) for 15 min by Mf
ACE10 versus MfWT. (L and M) Quantitative
ICC analysis of (L) CD36 expression and (M) amyloid-b uptake by untreated versus ACE-inhibitor pretreated (1 mM lisinopril overnight in RPMI
media + 0.3% BSA) MfACE10, following exposure to 100 nM fibril amyloid-b42 for either 0, 5 or 30 min. (N–Q) Individual correlation analysis
of the following: (N and O) surface fibril amyloid-b42 and Scara1 immunoreactive area at the binding time point in (N) Mf
WT and (O) MfACE10
(n =15 wells); (P and Q) surface fibril/oligomer amyloid-b42 and CD36 expression in Mf
ACE10 following a 15-min exposure to either fibril
amyloid-b42 or oligomer amyloid-b42. (R) Representative peak analysis in percentage mean fluorescence intensity (MFI) of Mf
ACE10 uptake
of HiLyte Fluor 647-labelled fibril amyloid-b42 at the 0-, 5-and 15-min time points. (S) Representative flow cytometry images of HiLyte Fluor 647-
labelled fibril amyloid-b42 MFI at the 15-min time point by F4/80
+ -MfWT versus -MfACE10. (T and U) Quantitative flow cytometry analysis of
HiLyte Fluor 647-labelled fibril amyloid-b42 MFI uptake at the 0-, 5- and 15-min time points by (T) Mf
WT or MfACE10 and by (U) untreated and
lisinopril pretreated MfACE10. The group mean  SEM as well as the fold reduction or increase and percentage decrease between groups are
shown. P5 0.05, P5 0.01, P5 0.001, P 5 0.0001; ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s or Sidak’s
post-test, while asterisks in parentheses signify a two-group comparison using the unpaired two-tailed Student t-test.
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ACE10 macrophages is significantly faster than that by
wild-type macrophages in the first 5, 15 and 60 min of
uptake assays (Fig. 3T and Supplementary Fig. 3M–P).
Interestingly, the ACE inhibitor lisinopril also had effects
on wild-type macrophages (peritoneal), significantly redu-
cing phagocytosis of amyloid-b42 fibrils by 450%
(Supplementary Fig. 3P), suggesting a role for endogenous
ACE in macrophage-mediated fibril amyloid-b42
phagocytosis.
Superior endosomal-lysosomal and
extracellular degradation of
amyloid-b42 conformers by ACE
10
macrophages
We next studied the capacity of ACE10 macrophages for
intra- and extracellular processing and degradation of the
three types of amyloid-b and the intracellular localization
of these amyloid-b42 species (Fig. 4). We conducted a series
of studies using bone marrow-derived ACE10 and wild-type
macrophages (Fig. 3A–C). Initial studies of wild-type
macrophages showed that when cells were exposed to
fibril amyloid-b42, the autophagy marker Beclin-1 relocated
to the cell nucleus (Fig. 4A). No difference in Beclin-1 ex-
pression was detected in ACE10 versus wild-type macro-
phages (data not shown). In contrast to Beclin-1
expression, fibril amyloid-b42 appears to co-localize
within early endosomes (EEA1) and lysosomal associated
membrane proteins 1 and 2 (Lamp-1 and Lamp-2) within
lysosomal vacuoles (Fig. 4B). Further analysis of amyloid-b
intake after a 15-min exposure to fibril amyloid-b42, prion
amyloid-b42, and oligomer amyloid-b42 showed co-localiza-
tion of the amyloid-b peptides within early endosomes
(Fig. 4C–F). The uptake of amyloid-b42 conformers and
co-localization in the EEA1+ endosomes was more appar-
ent in ACE10 macrophages than in wild-type cells. This was
observed for both the fibrillar and the soluble oligomeric
forms of amyloid-b42, although it was more intense for the
fibrillar form (Fig. 4C–F). A systematic evaluation of the
uptake of fibril, prion, and oligomer amyloid-b42 species by
ACE10 versus wild-type macrophages was undertaken.
Evaluation of the amyloid-b immunoreactive area within
EEA1+ endosomes (Fig. 4G) revealed that ACE10 cells con-
sistently had greater amounts of amyloid-b in the endoso-
mal-lysosomal pathway, presumably fated for intracellular
degradation. The larger increases in the ACE10 macro-
phages were most pronounced for the soluble amyloid-b
oligomers, as compared to prion rod-like structures and
fibrils, as they took up far more soluble amyloid than
that observed in wild-type cells (Fig. 4G and H; 21- to
40-fold increases, P 5 0.001–0.05).
To elucidate the relative abilities of wild-type and ACE10
macrophages to degrade amyloid-b in vitro, cells from each
genotype were cultured with fibril amyloid-b42 and
monitored for 18, 20 and 24 h (Fig. 4I and
Supplementary Fig. 4). At the end of this period, ELISA
was performed to measure extracellular amyloid-b42 levels
in the supernatant. There was a substantial reduction
(81%) in extracellular amyloid-b42 concentration in the
media of ACE10 macrophages compared to wild-type cell
media (Fig. 4I; P 5 0.001). We further performed an ex-
periment in which ACE10 macrophages were allowed to
take up and degrade fibril amyloid-b42 over 30 min in
the presence or absence of lisinopril (Fig. 4J). A subset of
ACE10 macrophages was treated under the same conditions
in an ice bath (0C) as a control. Amyloid-b42 concentra-
tions in the combined media and cell fraction of macro-
phages were analysed by performing ELISA. Again, these
data suggest that clearance of fibril amyloid-b42 is depend-
ent on ACE catalytic activity, as the group of ACE10
macrophages treated with lisinopril had significantly
higher amyloid-b42 concentrations than cells in which
ACE was catalytically active (Fig. 4J; P 5 0.0001).
Pro-healing immune profile of ACE10
macrophages exposed to Alzheimer’s
disease-related amyloid-b forms
To understand the biology of macrophages in response to
amyloid-b forms, both wild-type and ACE10 bone marrow-
derived macrophages were subjected to amyloid-b42 fibrils
and oligomers, and their morphologies and immune pheno-
types were assessed (Fig. 5 and Supplementary Fig. 5). As
seen in Fig. 5A and C, ACE10, as opposed to wild-type
macrophages, express 30% less iNOS and 80% more
arginase-1 prior to amyloid-b42 fibril exposure (P 5
0.05–0.01; Supplementary Fig. 5A and B). These differ-
ences became less apparent for arginase-1 after 5 min ex-
posure to amyloid-b42 peptides (Fig. 5C). The 30%
reduction of iNOS expression in ACE10 macrophages, com-
pared to wild-type macrophages, was sustained even after
1-h incubation with soluble amyloid-b42 oligomers
(Supplementary Fig. 5A). Further, considerable increases
in expression of the amyloid-b-degrading enzyme MMP9
were observed in ACE10 macrophages, both when unstimu-
lated and after exposure to amyloid-b42 fibrils over time
(Fig. 5D and E; 1.6–2.5-fold increase, P 5 0.001–
0.0001). Noticeably, there was a clear difference in the
physical form of the cells (Fig. 5F). The ACE10 macro-
phages were significantly more elongated and the percent-
age of elongated cells was higher than that in wild-type
cells in the unstimulated state (Fig. 5G; 2.2- and 4.4-fold
increase, respectively, P 5 0.001). Exposing these cells to
fibril amyloid-b42 for either 5 or 30 min resulted in an
increased ACE10-macrophage aspect ratio (elongation
factor), determined as the quotient of maximum cell pro-
cess length over cell body width (Fig. 5H; 2.0- and 1.7-fold
increase, respectively, P 5 0.0001). Hence, the cell pro-
cesses of wild-type macrophages were consistently shorter
than the processes of ACE-enhanced macrophages over
time (Fig. 5F–H). This type of elongated macrophage
morphology was previously associated with an anti-
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Figure 4 Intra- and extracellular degradation of pathological amyloid-b42 species by ACE
10 macrophages. (A) Representative
fluorescence micrograph of unstimulated (top) and fibril amyloid-b42 stimulated (bottom) Mf
WT immunolabelled for human amyloid-b (6E10;
green), autophagy marker Beclin-1 (red), and nuclei (blue). Merged channel panels show that in response to fibril amyloid-b42, Beclin-1 protein
moves to the nuclei (white arrows). (B) Representative fluorescence micrograph panel of fibril amyloid-b42 (fAb42) stimulated Mf
WT immu-
nolabelled for human amyloid-b (6E10; green), endosomal markers (EEA1, Lamp-1, Lamp-2, red), and nuclei (blue). (C and D) Representative
fluorescence micrograph of MfWT stimulated with the different fibril , prion rod-like and oligomer amyloid-b42 forms for 15 min and immu-
nolabelled for human amyloid-b (6E10; green), endosomal marker EEA1 (red), surface scavenger receptor CD36 (purple), and nuclei (blue). White
arrows indicate co-localizing of intracellular amyloid-b42 within EEA1
+ vesicles. (D) Higher magnification image of co-localized fibril amyloid-b42
within EEA1 + endosomes in MfWT (yellow spots). (E and F) Representative fluorescence micrograph of MfACE10 exposed to oligomer amyloid-
b42 (100 nM for 15 min) and immunolabelled for human amyloid-b (6E10; green), endosomal marker EEA1 (red), surface scavenger receptor
CD36 (purple) and nuclei (blue). White arrows indicate 6E10 + and EEA1 + co-localization. (F) Higher magnification image of co-localized
oligomer amyloid-b42 within EEA1
+ endosomes in MfACE10 (white arrows). (G and H) Quantitative analysis of co-localized 6E10 + and EEA1 +
immunoreactive area in unstimulated and fibril, prion rod-like and oligomer amyloid-b42-stimulated Mf
WT or MfACE10: (G) 6E10-IR area per
macrophage and (H) count of 6E10 + /EEA1 + vesicles using puncta count per macrophage. (I) Quantitative normalized analysis of percentage
reduction of extracellular fibril amyloid-b42 in media of Mf
WT versus MfACE10 over 18, 20 and 24 h. (J) Quantitative ELISA analysis of total intra-
and extracellular amyloid-b42 levels in the media and cell fraction of Mf
ACE10, following fibril amyloid-b42 for 30 min and either untreated,
lisinopril pretreated (1 mM lisinopril overnight in RPMI media + 0.3% BSA), or pre-placed in ice bath. The group mean  SEM as well as fold
increase and percentage decrease between groups are shown. P5 0.05, P5 0.01, P5 0.001, P5 0.0001. ns = non-significant, by two-
way or one-way ANOVA and Bonferroni’s post-test.
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inflammatory, pro-healing phenotype (McWhorter et al.,
2013; Rentsendorj et al., 2018).
Along this line, the immune profiles of ACE10 and wild-
type macrophages were further analysed using a highly sen-
sitive MSD multiplex inflammatory assay. The results are in
good accordance with the results obtained in vivo (Fig. 1M
and N) and show that stimulation of both wild-type and
ACE10 macrophages with fibril amyloid-b42 for 24 h
increased expression of TNFa (Fig. 5I; P 5 0.0001).
However, the magnitude of TNFa increase was significantly
lower in the ACE10 macrophages (Fig. 5I; P 5 0.001).
While IL-6, CXCL1, and IL-1b concentrations were also
elevated in both wild-type and ACE10 macrophages in re-
sponse to fibril amyloid-b42 stimulation, the degree of in-
crease was more reserved in the ACE10 macrophages than
in the wild-type cells (Fig. 5J–L and Supplementary Fig.
5C–F). Therefore, this assay showed that the expression
of pro-inflammatory cytokines is generally reduced in
ACE10 relative to wild-type macrophages when equiva-
lently stimulated with amyloid-b. Finally, we examined
the viability of wild-type versus ACE10 macrophages fol-
lowing a 24-h exposure to higher concentration of fibril
amyloid-b42 (1 mM). In this assay, on average 50% of
ACE10 macrophages appeared to survive, compared to
only 30% of the wild-type macrophages (Fig. 5M; P 5
0.05).
Discussion
Peripheral monocyte migration into the CNS, the role of
ACE, and their possible contribution in resisting
Figure 5 ACE overexpression in macrophages promotes a pro-healing, alternatively activated immune profile. (A) Fluorescence
micrographs of inducible nitric oxide synthase (iNOS, red), scavenger receptor CD36 expression (cyan), and nuclei (blue) in MfACE10 versus
MfWT (merged image on right). (B–D) Quantitative analysis showing (B) iNOS, (C) arginase-1, and (D) MMP9 in the immunoreactive area of
unstimulated (Un) and fibril amyloid-b42-stimulated Mf
ACE10 and MfWT at the 0- and 5-min time points. (E) Representative fluorescence
micrographs of MfWT and MfACE10 immunolabelled for MMP-9 (red) and nuclei (blue). (F) Representative bright-field images showing a mor-
phological difference in the cell process length of MfACE10 versus MfWTwith measurements of elongation (red lines). (G) Quantitative analysis of
elongation factor [ratio between total cell length and soma width (left) and percentage cell elongation (right) in unstimulated MfWT versus
MfACE10]. (H) Elongation factor in MfWT versus MfACE10 stimulated with fibril amyloid-b42 for 0, 5, and 30 min. (I–L) Quantitative MSD protein
assay of unstimulated (–) and stimulated with fibril amyloid-b42 [100 nM for 24 h ( + )] Mf
WT versus MfACE10 for the following cytokines:
(I) TNFa, (J) IL6, (K) CXCL1, and (L) IL1b. (M) Quantitative analysis of a cell viability MTTassay in MfWT versus MfACE10 after 24 h of exposure
to 1 mM fibril amyloid-b42 (n = 3 mice/genotype group, n = 6 wells/group; one-tailed Student t-test). Data from individual mouse, group mean 
SEM as well as fold increase and percentage decrease and increase between groups are shown. P 5 0.05, P 5 0.01, P 5 0.001,
P 5 0.0001. ns = non-significant, by two-way or one-way ANOVA and Bonferroni’s post-test, while asterisks in parentheses signify a
two-group comparison using the unpaired two-tailed Student t-test.
352 | BRAIN 2020: 143; 336–358 M. Koronyo-Hamaoui et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/143/1/336/5651064 by U
C
LA Biom
edical Library Serials, D
avid Teplow
 on 14 February 2020
Alzheimer’s-associated neuropathology and cognitive de-
cline are subjects of intense investigation and controversy
(Ajami et al., 2007; Butovsky et al., 2007; El Khoury et al.,
2007; Mildner et al., 2007; Lebson et al., 2010; Bernstein
et al., 2014b; Koronyo et al., 2015). In this study, we ad-
dressed these fundamental questions and demonstrated: (i)
in a partial bone marrow transplantation paradigm with
head shielding (protecting the brain from irradiation),
there was a measurable migration of peripheral monocytes
into the retina and brain parenchyma of AD+ mice. While
low in number, these cells critically localized around amyl-
oid-b plaques and reduced cerebral amyloid-b burden and
inflammation; (ii) engrafted ACE10 monocytes in the brains
of AD+ mice are found at about three times higher num-
bers than wild-type cells and are more effective in restrict-
ing neuropathology; (iii) compared to wild-type
macrophages, ACE10 cells in AD+ mouse brains express
60% lower levels of TNFa and 3.2-fold higher IGF1,
associated with restricting neurodegeneration and cognitive
deficits; (iv) non-invasive retinal imaging demonstrates the
feasibility of tracking the movements of GFP+ -monocytes
into the retina of AD+ mice in real time; (v) adoptive trans-
fer of CD115+ ACE10 monocytes into the peripheral blood
of symptomatic AD+ mice, an irradiation-free translational
approach, is highly effective in reducing vascular amyloid-
osis and preserving synapses and cognitive function; (vi)
ACE10 macrophages exhibit strikingly unique immunolo-
gical profiles, with enhanced surface receptors and aug-
mented ability to bind, internalize, degrade, and destroy
fibrillar, prion rod-like, and soluble oligomeric amyloid-
b42 species; and (vii) the elongated cell morphology and
molecular signature of ACE10 macrophages suggest an
anti-inflammatory, pro-healing, and highly resilient pheno-
type that may help fight against Alzheimer’s disease.
Although several studies have demonstrated the ability of
human blood mononuclear cells, monocytes and macro-
phages, to phagocytose fibrillar amyloid-b and remove pla-
ques from the brains of Alzheimer’s disease model mice
(Malm et al., 2005; Simard et al., 2006; Butovsky et al.,
2007; Fiala et al., 2007; Lai and McLaurin, 2012; Koronyo
et al., 2015), their direct involvement in the clearance of
non-fibrillar forms of amyloid-b and possible neuroprotec-
tion in Alzheimer’s disease is still highly debated (Fiala
et al., 2005; Mildner et al., 2007). Moreover, previous
studies did not measure the degree of clearance of defined
and stabilized amyloid-b42 structures associated with
Alzheimer’s disease neuropathology such as prion rod-like
assemblies or soluble oligomers. While amyloid-b plaque
burden in the brain appears very limited in predicting cog-
nitive decline (Jansen et al., 2018) and may even serve as a
mediator of an effective innate immune response against
foreign pathogens (Soscia et al., 2010), soluble amyloid-
b42 oligomers and prion rod-like structures have been
shown to be highly neurotoxic and more elusive to phago-
cytic immune cells (Selkoe, 2008; Shankar et al., 2008).
Because of the meta-stability of these amyloid-b42 assem-
blies, structure-activity determinations with respect to
macrophage responses have been problematic. Here, using
structurally stabilized oligomers and well-characterized
prion rod-like and fibrillar amyloid-b42, we were able to
accomplish these determinations with respect to binding
efficacy, internalization, and degradation by wild-type and
ACE10 macrophages. Our studies show that in the wild-
type cells, oligomers of amyloid-b42 are found in very
low amounts in endosomes and lysosomes, the cellular ubi-
quitin/proteasome machinery that degrades misfolded pro-
teins (Majumdar et al., 2008). Yet, ACE overexpression
and enzymatic function significantly shifted macrophage be-
haviour and their ability to also target amyloid-b42 oligo-
mers to endosomes (up to 40 times higher as compared to
those found in wild-type macrophages; Fig. 4C–H). As a
result of the subcellular localization of amyloid-b42 in
ACE10 macrophages and the increased levels of amyloid-
b-degrading enzymes (i.e. ACE, MMP9), the net concentra-
tions of amyloid-b42 remaining after a 24-h incubation with
ACE10 versus wild-type macrophages were as much as
80% lower.
The unique morphological and immunological profiles of
ACE10 macrophages in response to amyloid-b42 were as-
sessed using various techniques. One mechanism that could
explain this superior performance is increased surface ex-
pression of scavenger receptors, including Scara1, TREM2,
CD163, and especially CD36, all of which have been pre-
viously shown to facilitate amyloid-b internalization and
clearance by myelomonocytic cells (Koronyo et al., 2015;
Rentsendorj et al., 2018). In particular, Scara1 expression
was tightly associated with the extent of phagocytosis of
amyloid-b42 fibrils, but less so for prion rod-like structures
and soluble oligomers. In the ACE10 macrophages, CD36
expression was drastically elevated (increased 6- to 36-fold)
and tightly associated with increased uptake of all three
types of amyloid-b assemblies. In contrast, the wild-type
macrophages displayed no association between surface
CD36 expression and uptake of amyloid-b42 fibrils and
oligomers, though a strong correlation was observed with
rod-like structures. The reason for this phenomenon is cur-
rently unknown. Future studies are needed to better under-
stand the molecular immune mechanisms at play to remove
pathogenic forms of amyloid-b. Further in vitro techniques
supported the enhanced molecular characteristics of the
ACE10 macrophages, before and after exposure to amyl-
oid-b42 conformers. All assay findings consistently sug-
gested that these bone marrow-derived cells exhibit an
anti-inflammatory (i.e. low TNFa and iNOS, high IGF1,
arginase-1, and MMP9) and a pro-healing/protective (i.e.
elongated cell morphology) phenotype. These effects were
dependent on ACE enzymatic activity and were eliminated
when treating the cells with ACE inhibitors. In contrast,
previous studies demonstrated that peritoneal-derived
ACE10 macrophages, under conditions of acute foreign in-
vasion or cancer models, enhanced their effective immune
reactivity in the periphery to resolve disease while exhibit-
ing a highly pro-inflammatory profile (Bernstein et al.,
2018). These diverse phenotypes of the ACE10 cells may
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suggest their ability to promptly and effectively respond to
insults in a tissue- and disease-specific manner. This vari-
ation in response could also be due to the different stages
of healing for which these cells are recruited (i.e. chronic
inflammation versus acute injury); nonetheless, their remed-
ial capacity is strongly evident. The enhanced immune re-
sponse of ACE10 macrophages to acute infection or tumour
has repeatedly been shown to not be dependent on the
production of angiotensin II or any angiotensin peptide
by ACE (reviewed in Bernstein et al., 2018). While this
was not formally tested in our study, we believe it most
likely that the unique phenotype of the ACE10 macrophages
here are probably also due to other mechanisms besides
angiotensin II. We further note a recent study documenting
that ACE cleaves dozens, if not hundreds, of different pep-
tide substrates (Semis et al., 2019).
Our in vivo studies assessed the exclusive contribution of
peripherally derived ACE10 monocytes and macrophages in
attenuating neuropathology and cognitive deficits in murine
models of Alzheimer’s disease. Mounting evidence suggests
a protective role for innate immune cells in the CNS (El
Khoury et al., 2007; Koronyo-Hamaoui et al., 2009;
Shechter et al., 2009; Lebson et al., 2010; Bernstein et
al., 2014b; Koronyo et al., 2015), though some studies
have failed to show migration of these cells under neuro-
degenerative conditions (Mildner et al., 2007), or showed
monocyte migration to CNS without effects on behaviour
and cerebral amyloid-b levels (Prokop et al., 2015; Varvel
et al., 2015; Cronk et al., 2018). Our group previously
demonstrated that peripherally derived GFP-labelled mono-
cytes are naturally recruited to brains of Alzheimer’s dis-
ease model mice (Butovsky et al., 2006, 2007; Koronyo-
Hamaoui et al., 2009; Bernstein et al., 2014b) and that
they directly reduce neuropathology and preserve cognition
(Koronyo et al., 2015). This irradiation- and pharmaco-
logically-free approach substantially enriched the CD115+
bone marrow-derived inflammatory monocyte subset in the
peripheral blood of AD+ mice, resulting in spontaneous
recruitment of these cells to the CNS, and led to diminished
soluble and insoluble amyloid-b40,42 levels and astrocytosis
as well as increased post-synaptic density and preservation
of learning and memory (Koronyo et al., 2015; Rentsendorj
et al., 2018). When targeting ACE overexpression in
macrophages, our earlier studies reported major therapeutic
effects in protecting against melanoma and microbial infec-
tions (Bernstein et al., 2014a, 2018). Our current investi-
gation also strongly suggests neuroprotective effects of
ACE10 macrophages in Alzheimer’s disease mouse models.
In accordance, administration of the ACE inhibitor capto-
pril to Alzheimer’s disease mice was reported to increase
cerebral amyloid-b deposition (Zou et al., 2007). Here,
ACE-overexpressing macrophages were consistently potent
in clearing amyloid-b42 conformers—even the most elusive
non-fibrillar forms—and successfully migrated into the
mouse brain and retina with an enhanced ability to inhibit
pathogenesis. While it appears that ACE overexpression in
both the resident microglia and peripheral myelomonocytes
work synergistically to restrict Alzheimer’s disease-asso-
ciated pathology and improve cognition in animal models
(Bernstein et al., 2014b; Koronyo-Hamaoui et al., 2014),
the extent of the effect by peripheral ACE10 macrophages
alone was nonetheless substantial, especially with regards
to cerebral vascular amyloidosis. Because of growing re-
ports on the key role of vascular abnormalities in
Alzheimer’s-related cognitive decline (Ellis et al., 1996;
Wyss-Coray et al., 2001; Herzig et al., 2006; Rentsendorj
et al., 2018; Nation et al., 2019), the beneficial effects of
ACE10 macrophages on reducing vascular amyloidosis
(CAA severity score) and GFAP+ astroglial reactivation
may indicate protection to the neurovascular unit and
could explain synaptic and cognitive preservation seen in
these mice. Similarly, previous studies in murine
Alzheimer’s disease models showed that blood infusion
with either wild-type or neprilysin-enriched monocytes miti-
gated neuropathology and cognitive deficits (Lebson et al.,
2010; Koronyo et al., 2015) and monocyte depletion exa-
cerbated amyloid-b-plaque pathology (Butovsky et al.,
2007; El Khoury et al., 2007).
Specifically, we have shown by two in vivo approaches
that ACE-overexpressing monocytes are more effective in
ameliorating Alzheimer’s disease-like pathology and preser-
ving cognition in symptomatic murine models of
Alzheimer’s disease. Our data showed that even partial
bone marrow replacement with ACE10 cells (after partial-
body irradiation, which avoids the skull area to prevent
damage to the blood–brain barrier) leads to a substantial
3-fold increase of ACE10 monocytes in the brain, signifi-
cantly decreasing cerebral amyloid-b plaques, amyloid-b’s
soluble forms, and astrocytosis. Increased in vivo recruit-
ment of ACE10 macrophages could be, at least in part,
attributed to enhanced secretion of MMP9, an enzyme
known to facilitate transmigration of immune cells through
the blood–brain barrier (Chaturvedi and Kaczmarek,
2014). These brain-engrafted cells also exhibited 60%
lower TNFa levels and 3.2-fold higher IGF1, adding a
major advantage of this therapeutic approach. TNFa is a
key pro-inflammatory cytokine that in excess can induce
oxidative stress related to the release of iNOS and reactive
oxygen species, which are tightly associated with neurotox-
icity and functional decline. Moreover, IGF1 is a brain re-
generative, neurogenesis-promoting neurotrophic factor
with recently discovered anti-inflammatory functions
(Gasparini and Xu, 2003). Cerebral IGF1 in murine
models of Alzheimer’s disease was shown to be elevated
following immunomodulation interventions involving
increased brain-infiltrating monocytes/macrophages and
cognitive preservation (Butovsky et al., 2006; Koronyo-
Hamaoui et al., 2009), and another report has demon-
strated its direct involvement in reducing amyloid-b
plaque burden (Carro et al., 2002). Such substantial
changes in TNFa and IGF1 levels in a chronically inflamed
brain by ACE10 macrophages could, if translated into
humans, potentially alter the course of Alzheimer’s disease
and critically preserve synapses and cognition. This
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hypothesis is supported by our observations from the adop-
tive transfer studies in which enriching the peripheral blood
of symptomatic AD+ mice with CD115+ -MoACE10 cells
resulted in improved cognitive function (Barnes maze test)
and pre- and post-synaptic preservation.
In comparison, our previous studies in murine models
of Alzheimer’s disease involving life-long replacement of
CNS-resident microglia and peripheral monocyte and
macrophage populations with the ACE-overexpressing
cells resulted in an almost complete elimination of cerebral
amyloid-b burden, astrocytosis, and full preservation of
cognitive functions, similar to the levels seen in the wild-
type mice (Koronyo-Hamaoui et al., 2009; Bernstein et al.,
2014b, 2018; Rentsendorj et al., 2018). As briefly men-
tioned above, here partial bone marrow replacement or
short-term blood enrichment with ACE10 macrophages
(once a month for 3 months) in animals that already
have Alzheimer’s disease-like symptoms limited neuropath-
ology by 30–40% (especially vascular amyloidosis), yet re-
markably restored cognitive functions to levels
indistinguishable from those found in cognitively normal
wild-type mice.
Conclusion and translational
implications
Despite considerable progress in understanding the aeti-
ology of Alzheimer’s disease, an effective treatment remains
elusive. The therapeutic potential evidenced in our studies
favours selective increase of ACE (Al Mulhim et al., 2019),
a peptidase capable of destroying amyloidogenic peptides
and enhancing neuroprotective phenotype, in peripheral in-
flammatory cells that can migrate into the brain and
powerfully support tissue-healing processes and cognition.
For the first time, we demonstrate a superior ability of
ACE10 macrophages to eradicate amyloid-b assemblies,
particularly Alzheimer’s-associated non-fibrillar, oligomeric
amyloid-b structures. The infiltration of these cells to the
CNS was further validated through live non-invasive ima-
ging of the retina, providing a feasible method to track
immune cell migration during disease progression.
Moreover, this study reveals the beneficial roles of
CD115+ bone marrow-derived monocyte subsets and
ACE in resisting Alzheimer’s pathology, especially import-
ant in light of large-scale human genetic studies identifying
ACE and innate immune genes as prominently related to
Alzheimer’s disease (Kehoe et al., 1999, 2003, 2004;
Narain et al., 2000; Elkins et al., 2004; Kolsch et al.,
2005; Lehmann et al., 2005; Meng et al., 2006;
Jochemsen et al., 2014; de Oliveira et al., 2018; Marioni
et al., 2018; Kunkle et al., 2019). Further, the marked re-
duction of Alzheimer’s-associated pathology with targeted
ACE expression in inflammatory cells raises a clinically im-
perative question related to the outcome of life-long use of
ACE inhibitors in the large number of patients with heart-
related conditions (including high blood pressure), or com-
monly prescribed anti-inflammatory drugs (i.e. NSAIDs).
For example, our results and other published data suggest
caution in the use of ACE inhibitors, perhaps prioritizing
those that do not penetrate the brain, such as benazepril,
enalapril or quinapril (Kehoe et al., 2013). We envision the
reported approach to be applicable to humans via isolation
of monocytes from bone marrow or circulating blood, ma-
nipulation in vitro to overexpress ACE, followed by reinfu-
sion of the modified cells to the patient. Future direction
will focus on developing the practical and clinical protocols
for each of these steps. It could involve the use of genetic-
ally modified stem cells or viral vectors to modify the iso-
lated immune cells.
In conclusion, this study may alter the vision of
Alzheimer’s disease in human health in two ways: increased
attention to potential neuropathological consequences of
ACE inhibitors and anti-inflammatory drugs, and discovery
of a novel Alzheimer’s disease immunotherapy to deliver
ACE and therapeutic monocytes to the site of Alzheimer’s
disease pathological manifestation.
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